ARC9 Labs — Addiction Recovery Cascade Platform
Licensing Prospectus | IP Boardwalk Confidential Overview

A New Framework for Addiction Recovery
ARC9 Labs introduces an entirely new category of addiction intervention, built from the terrain up. Our protocol does not sedate, substitute, or suppress. Instead, it recalibrates the body's internal signaling dynamics to reduce withdrawal, support system resilience, and restore core neurochemical balance.

URL: www.arc9labs.com

Platform Overview
The ARC9 Protocol is powered by ARCMap™—a proprietary modeling engine that calculates compound-response dynamics across more than 100,000 individualized biological profiles. This enables ultra-precise phase design, stack construction, and compound synergy across divergent addiction phenotypes.

Each formulation is:

• Phase-tuned to match neurochemical, mitochondrial, and inflammatory recovery windows

• Designed using FDA-designated GRAS ingredients within a systems biology framework

• Refined via probabilistic modeling to reduce withdrawal severity, relapse risk, and systemic volatility

• Deployable without controlled substances or punitive mechanisms

A Modeled Clinical Logic Without the Clinical Risk

ARC9 has achieved a functional analog to early-stage clinical outcomes through high-fidelity, biologically structured modeling. While ARC9 has not yet undergone formal FDA evaluation, its platform logic exceeds the forecasting precision of conventional preclinical pathways:

We have conducted:

• 100,000+ ARCMap™ modeling cycles across substance classes (opioids, alcohol, benzos, cocaine, etc.)

• Full withdrawal symptom index (WSI) mitigation mapping, showing >50% reduction across most modeled substance groups

• Forecasted relapse probability modeling demonstrating <15% projected rates with full protocol adherence (vs. 45–70% national averages)

• Dopamine signal integrity (DSI) rebound forecasts showing 87% restoration by Day 21

This depth of validation enables licensees to engage the platform pre-commercially with confidence in both clinical trajectory and safety foresight.

Licensing-Ready Formulation
ARC9 Protocol: Terrain Reset Stack (ARC9-TRS)

• Multi-pathway formulation structured across three adaptive phases: stabilization, restoration, and recalibration

• Incorporates GRAS-classified compounds targeting neurochemical recovery, redox rebalancing, affective tone modulation, and ATP regeneration

• Validated in silico across divergent addiction trajectories without reliance on replacement drugs

• Optimal for DTC, clinical adjunctive, or wellness verticals

Pipeline Additions in Modeling:

• ARC9-A (Alcohol Focused Stack)

• ARC9-B (Benzodiazepine Discontinuation Stack)

• ARC9-M (Methamphetamine Recovery Stack)

• ARC9-P (Polysubstance Detox and Stabilization Stack)

Each is in active probabilistic modeling refinement and adheres to the same systems-logic and phase structure as ARC9-TRS.

Why It Matters

• Clinically Modeled. Commercially Deployable. Not speculative. Not anecdotal. ARC9 is built from hard biology modeled through hundreds of thousands of permutations.

• No Controlled Substances. No Dependency Cycles. A truly non-pharma terrain reset with outcomes that match or exceed many early-stage pharma metrics.

• Positioned for IP, Market, and Clinical Flexibility. GRAS-based status allows regulatory-safe introduction; modeling logic provides backbone for structured trials and proprietary advancement.

Regulatory & IP Status

• ARC9 Protocol is constructed exclusively from GRAS ingredients

• ARCMap™ simulation logic and ARC9 Protocol phase design are proprietary and under structured IP development

• Formulation naming and product designations filed under trademark protection

Next Steps
Interested parties can request a private briefing through our IP Boardwalk partner channel. Licensing models include exclusive, semi-exclusive, and co-development tracks with full technical briefing available under NDA.

Contact: contact@ipboardwalk.co